The study will involve 100 patients with panic disorders with agoraphobia who have shown good and stable response to uniform treatment with imipramine 2.25 mg/kg/day. The first 100 patients to show marked response at both the 16 and 24 week assessments of active treatment will be randomly assigned to double blind maintenance on the same dose of imipramine or placebo substitution with planned assessments every two months for a duration of 1 year (months 0-12). This will be followed by a one year double blind extension phase (months 12-24) during which placebo patients will continue in the same condition while imipramine patients will imdergo a second randomization to continued imipramine maintenance or to placebo substition. Finally, all subjects, completers/relapsers as well as dropouts from the different stages of double blind treatment will be followed in an open discontinuation/no pill paradigm for up to four years post randomization. Repeated assessments will include clinician and patient rating of panic, phobia, anxiety and dysphoria/depression, operationalized criteria of response and relapse, plasma concentration of imipramine and metabolites and the assessment of life events, personality and health status/well being. The primary aim of the study is to assess the extent of reversals/relapse due specifically to withdrawal of imipramine over a 2 year period and to characterize imipramine's long term effects as well as the net beneficial effects of imipramine maintenance in this disorder. In addition, the project will provide systematic data on the comparative rate of relapse after acute and maintenance treatments and rigorous longitudinal data of open discontinuation/relapse after varying lengths of imipramine maintenance. The results should have significance for the long term management of panic disorder patients i.e., the extent to which maintenance pharmacotherapy is necessary and for how long, the risk benefit ration of long term treatment and compliance, and the quality of life and cost effectiveness implications of maintenance/discontinuation in this disorder.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH042730-12
Application #
2674889
Study Section
Treatment Assessment Review Committee (TA)
Program Officer
Lebowitz, Barry D
Project Start
1986-09-01
Project End
2001-04-30
Budget Start
1999-05-01
Budget End
2000-04-30
Support Year
12
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Mavissakalian, Matig R; Perel, James M (2002) Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J Clin Psychopharmacol 22:294-9
Mavissakalian, Matig; Perel, James; Guo, Shenyang (2002) Specific side effects of long-term imipramine management of panic disorder. J Clin Psychopharmacol 22:155-61
Mavissakalian, Matig R; Guo, Shenyang (2002) Predictors of entering a long-term drug treatment study of panic disorder. Compr Psychiatry 43:88-94
Mavissakalian, M R; Perel, J M (2001) 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. Ann Clin Psychiatry 13:63-7
Mavissakalian, M R; Zamar, N (2000) Generalized anxiety disorder versus panic disorder: participation in controlled efficacy trials. Compr Psychiatry 41:253-8
Mavissakalian, M R; Schmier, J K; Flynn, J A et al. (2000) Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder. Pharmacoeconomics 18:383-91
Mavissakalian, M R; Perel, J M (2000) The side effects burden of extended imipramine treatment of panic disorder. J Clin Psychopharmacol 20:547-55
Mavissakalian, M R; Perel, J M (1999) Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 56:821-7
Mavissakalian, M R; Perel, J M; Talbott-Green, M et al. (1998) Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. Biol Psychiatry 43:848-54
Mavissakalian, M R; Ryan, M T (1998) Rational treatment of panic disorder with antidepressants. Ann Clin Psychiatry 10:185-95

Showing the most recent 10 out of 37 publications